References 30388

References

8/18/03 Emotional Wellness

1. Kessler RC et al. The epidemiology of major depressive disorder:results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289, 23:3095-105, 2003.www.jama.com.

2. Bennett MP et al. The effect of mirthful laughter on stress and naturalkiller cell activity. Altern Ther Health Med. 9, 2:38-45,2003.

3. Rogers PJ. A healthy body, a healthy mind: long-term impact of diet onmood and cognitive function. Proc Nutr Soc. 60, 1:135-43,2001. www.cabi-publishing.org/journals/pns.

4. Gottfries CG. Late life depression. Eur Arch PsychiatryClin Neurosci. 251 Suppl 2:II57-61, 2001. http://www.springerlink.com/link.asp?id=101492.

5. Jorm AF et al. Effectiveness of complementary and self-help treatmentsfor depression. Med J Aust. 176 Suppl:S84-96, 2002. www.mja.com.au. 

6. Tiemeir H et al. Vitamin B12, folate and homocysteine in depression:the Rotterdam Study. Am J Psychiatry. 159, 12:2099-101,2002. http://ajp.psychiatryonline.org. 

7. Bjelland I et al. Folate, vitamin B12, homocysteine and the MTHFR677C-T polymorphism in anxiety and depression: The Hordaland Homocysteine Study.Arch Gen Psychiatry. 60, 6:618-26, 2003. http://archpsyc.ama-assn.org.

8. Morris MS et al. Depression and folate status in the U.S. population.Psychother Psychosom. 72, 2:80-7, 2003. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223864.

9. Taylor MJ et al. Folate for depressive disorders (Cochrane Review). Cochrane Database SystRev. 2:CD003390, 2003. www.cochrane.org.

10. Coppen A, Bailey J. Enhancement of the antidepressant action offluoxetine by folic acid: a randomized, placebo controlled trial. JAffect Disord. 60, 2:121-30, 2000. www.elsevier.nl/locate/jad.

11. Penninx BW et al. Vitamin B(12) deficiency and depression inphysically disabled older women: epidemiologic evidence from the WomensHealth and Aging Study. Am J Psychiatry. 157, 5:715-21,2000. http://ajp.psychiatryonline.org.

12. McCarty MF. High-dose pyridoxine as an anti-stress strategy. MedHypotheses. 54, 5:803-7, 2000. www.sciencedirect.com/science/journal/03069877.

13. Lerner V et al. Vitamin B6 as add-on treatment in chronicschizophrenic and schizoaffective patients: a double blind, placebo controlledstudy. J Clin Psychiatry. 63, 1:54-8, 2002. www.psychiatrist.com.

14. Sher L. Role of selenium depletion in the effects of dialysis on moodand behavior. Med Hypotheses. 59, 1:89-91, 2002. www.sciencedirect.com/science/journal/03069877.

15. Sher L. Role of selenium depletion in the etiopathogenesis ofdepression in patients with alcoholism. Med Hypotheses. 59,3:330-3, 2002. www.sciencedirect.com/science/journal/03069877.

16. McLeod MN, Golden RN. Chromium treatment of depression. Int JNeuropsychopharmacol. 3, 4:311-14, 2000. http://uk.cambridge.org/journals/pnp.

17. Davidson JR et al. Effectiveness of chromium in atypical depression: aplacebo-controlled trial. Biol Psychiatry. 53, 3:261-4,2003. www-east.elsevier.com/bps.

18. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatmentof depression: a review of the evidence. Am J Clin Nutr.76, 5:1158S-61S, 2002. www.ajcn.org.

19. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability oforal and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) inthe treatment of major depression: comparison with imipramine in 2 multicenterstudies. Am J Clin Nutr. 76, 5:1172S-6S, 2002. www.ajcn.org.

20. Hibbeln JR. Fish consumption and major depression. Lancet. 151, 9110:1213, 1998.www.thelancet.com.

21. Tanskanen A et al. Fish consumption and depressive symptoms in thegeneral population in Finland. Psychiatr Serv. 52,4:529-31, 2001. http://psychservices.psychiatryonline.org.

22. Hibbeln JR. Seafood consumption, the DHA content of mothers milkand prevalence rates of postpartum depression: a cross-national, ecologicalanalysis. J Affect Disord. 69, 1-3:15-29, 2002. www.elsevier.nl/locate/jad.

23. Haag M. Essential fatty acids and the brain. Can J Psychiatry. 48, 3:195-203, 2003.www.cpa-apc.org/Publications/cjpHome.asp.

24. Colin A et al. Lipids, depression and suicide. Encephale. 29, Pt. 1:49-58, 2003.http://psydoc-fr.broca.inserm.fr/bibliothq/revues/Encephale.html.

25. Tiemeirer H et al. Plasma fatty acid composition and depression areassociated in the elderly: the Rotterdam Study. Am J Clin Nutr. 78, 1:40-6, 2003.www.ajcn.org.

26. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid tomaintenance medication treatment for recurrent unipolar depressive disorder. Am JPsychiatry. 159:477-9, 2002. http://ajp.psychiatryonline.org.

27. Peet M, Horrobin DF. A dose-ranging study of the effects ofethyl-eicosapentaenoate in patients with ongoing depression despite apparentlyadequate treatment with standard drugs. Arch Gen Psychiatry. 59, 10:913-9, 2002.http://archpsyc.ama-assn.org.

28. Mamlakis G, Tornaritis M, Kafatos A. Depression and adipose essentialpolyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 67, 5:311-8, 2002.www.harcourt-international.com/journals/plef.

29. Marangell LB et al. A double blind, placebo-controlled study of theomega-3 fatty acid docosahexaenoic acid in the treatment of major depression.Am J Psychiatry. 160, 5:996-8, 2003. http://ajp.psychiatryonline.org.

30. Llorente AM et al. Effect of maternal docosahexaenoic acidsupplementation on postpartum depression and information processing. Am J ObstetGynecol. 188, 5:1348-53, 2003. www.mosby.com/Mosby/Periodicals/Medical/AJOG/ob.html.

31. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review.Psychopharmacology (Berl). 165, 2:97-110, 2003. www.springerlink.com/link.asp?id=fg8x4e7gnllc3lk4.

32. Wolkowitz OM, Epel ES, Reus VI. Stress hormone-relatedpsychopathology: pathophysiological and treatment implications. World J BiolPsychiatry. 2, 3:115-43, 2001.

33. Young AH, Gallagher P, Porter RJ. Elevation of thecortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am JPsychiatry. 159, 7:1237-9, 2002. http://ajp.psychiatryonline.org.

34. Sondergaard HP, Hansson LO, Theorell T. Elevated blood levels ofdehydroepiandrosterone sulphate vary with symptom load in posttraumatic stressdisorder: findings from a longitudinal study of refugees in Sweden. PsychotherPsychosom. 71, 5:298-303, 2002. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223864.

35. Rohr UD, Herold J. Melatonin deficiencies in women. Maturitas. 41 Suppl 1:S85-104, 2002.www.sciencedirect.com/science/journal/03785122.

36. Tuunainen A et al. Depression and endogenous melatonin inpostmenopausal women. J Affect Disord. 69, 1-3:149-58,2002. www.elsevier.nl/locate/jad.

37. Fountoulakis KN et al. Morning and evening plasma melatonin anddexamethasone suppression test in patients with nonseasonal major depressivedisorder from northern Greece (latitude 40-41.5 degrees). Neuropsychobiology. 44, 3:113-7, 2001.http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=224082.

38. Birdsall TC. 5-hydroxytryptophan: a clinically-effective serotoninprecursor. Altern Med Rev. 3, 4:271-80, 1998.

39. Shaw K, Turner J, Del Mar C. Cochrane Database Syst Rev.1:CD003198, 2002. www.cochrane.org.

40. Hammerness P et al. St. Johns wort: A systematic review of adverseeffects and drug interactions for the consultation psychiatrist. Psychosomatics. 44, 4:271-82, 2003.http://psy.psychiatryonline.org.

41. Butterweck V. Mechanism of St. Johns wort in depression: What isknown? CNS Drugs. 17, 8:539-62, 2003. http://www.adis.com/page.asp?objectID=40.

42. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum(St. Johns wort) in major depressive disorder: a randomized controlled trial.JAMA. 287, 14:1807-14, 2002. www.jama.com.

43. Lecrubier Y et al. Efficacy of St. Johns wort extract WS 5570 inmajor depression: a double blind, placebo-controlled trial. Am JPsychiatry. 159, 8:1361-6, 2002. http://ajp.psychiatryonline.org.

44. Schwabe W. St. Johns wort extract WS 5572 in minor to moderatelysevere depression. Effectiveness and tolerance of 600 and 1,200 mg activeingredient daily. Fortschr Med Orig. 119, 3-4:119-28, 2001.

45. Singh YN, Singh NN. Therapeutic potential of kava in the treatment ofanxiety disorders. CNS Drugs. 16, 11:731-43, 2002. http://www.adis.com/page.asp?objectID=40.

46. Boerner RJ et al. Kava-kava extract LI 150 is as effective asOpipramol and Buspirone in generalized anxiety disorder--an 8-week, randomized,double blind multi-center clinical trial in 129 outpatients. Phytomedicine. 10 Suppl 4:38-49, 2003.http://matilde.ingentaselect.com/vl=3466232/cl=64/nw=1/rpsv/cw/urban/09447113/contp1.htm.

47. Connor KM, Davidson JR. A placebo-controlled study of kava kava ingeneralized anxiety disorder. Int Clin Psychopharmacol. 17,4:185-8, 2002. www.intclinpsychopharm.com.

48. Stickel F et al. Hepatitis induced by kava (Piper methysticumrhizoma). J Hepatol. 39, 1:62-7, 2003. www.jhep-elsevier.com.

49. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database SystRev. 1:CD003383, 2003. www.cochrane.org.

50. Wheatley D. Stress-induced insomnia treated with kava and valerian:singly and in combination. Hum Psychopharmacol. 16,4:353-356, 2001. www.interscience.wiley.com/jpages/0885-6222.

51. Cropley M et al. Effect of kava and valerian on human physiologicaland psychological responses to mental stress assessed under laboratoryconditions. Phytother Res. 16, 1:23-7, 2002. www.interscience.wiley.com.

52. Hadley S, Petry JJ. Valerian. Am Fam Physician.67, 8:1755-8, 2003. www.aafp.org/afp.

53. Hemmeter U et al. Polysomnographic effects of adjuvant ginkgo bilobatherapy in patients with major depression medicated with trimipramine. Pharmacopsychiatry. 34, 2:50-9, 2001.www.thieme.de/pharmaco.

54. Huen MS et al. 5,7-Dihydroxy-6-methoxyflavone, a benzodiazepine siteligand isolated from Scutellaria baicalensis Georgi, with selective antagonisticproperties. Biochem Pharmacol. 66, 1:125-32, 2003. www.elsevier.com/locate/biochempharm.

55. Hui KM et al. Anxiolytic effect of wogonin, a benzodiazepine receptorligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 64, 9:1415-24, 2002.www.elsevier.com/locate/biochempharm.

56. Sufka KJ et al. Anxiolytic properties of botanical extracts in thechick social separation-stress procedure. Psychopharmacology (Berl). 153, 2:219-24, 2001.www.springerlink.com/link.asp?id=fg8x4e7gnllc3lk4.